Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells 2,410 Shares of Company Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 2,410 shares of the firm’s stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $620.07, for a total transaction of $1,494,368.70. Following the completion of the transaction, the chief executive officer directly owned 386,892 shares in the company, valued at $239,900,122.44. This represents a 0.62% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Medpace Stock Up 1.0%

Shares of NASDAQ:MEDP traded up $6.17 during trading on Tuesday, hitting $622.11. 249,674 shares of the company traded hands, compared to its average volume of 331,499. The stock has a market capitalization of $17.36 billion, a price-to-earnings ratio of 36.47, a PEG ratio of 2.76 and a beta of 1.15. The business’s fifty day moving average is $596.41 and its 200-day moving average is $517.30. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same period in the prior year, the firm earned $3.10 EPS. The business’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. BMO Capital Markets upped their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Finally, Jefferies Financial Group reaffirmed a “hold” rating on shares of Medpace in a report on Monday, September 14th. Three equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $595.20.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of MEDP. Schulhoff & Co. Inc. grew its position in Medpace by 1.1% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock worth $1,237,000 after buying an additional 25 shares in the last quarter. Balefire LLC raised its holdings in Medpace by 6.1% in the 1st quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after acquiring an additional 26 shares in the last quarter. Root Financial Partners LLC raised its holdings in Medpace by 34.1% in the 1st quarter. Root Financial Partners LLC now owns 122 shares of the company’s stock valued at $59,000 after acquiring an additional 31 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Medpace by 2.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,158 shares of the company’s stock valued at $613,000 after acquiring an additional 32 shares during the period. Finally, Handelsbanken Fonder AB lifted its position in shares of Medpace by 0.6% during the 2nd quarter. Handelsbanken Fonder AB now owns 7,020 shares of the company’s stock valued at $3,718,000 after acquiring an additional 40 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.